<DOC>
	<DOCNO>NCT00234195</DOCNO>
	<brief_summary>- To evaluate efficacy bupropion extend release ( Wellbutrin XL™ ) treatment Major Depressive Disorder woman breast cancer . - To evaluate tolerability bupropion extended-release ( Wellbutrin XL™ ) patient</brief_summary>
	<brief_title>Wellbutrin XL , Major Depressive Disorder Breast Cancer</brief_title>
	<detailed_description>This research study woman diagnose breast cancer major depression . Women breast cancer depress may report great pain , poor quality life bad overall functioning without depression . The study determine whether bupropion extend release ( Wellbutrin XLTM ) useful lessen symptom depression woman breast cancer . One reason conduct research bupropion extend release ( Wellbutrin XLTM ) instead another antidepressant bupropion lower likelihood cause side effect weight gain , sexual dysfunction , fatigue , may important woman breast cancer may even beneficial effect symptom . Bupropion extend release ( Wellbutrin XL™ ) approve United States Food Drug Administration ( FDA ) treatment major depression .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Women age 18 year old Diagnosis breast cancer , confirm histopathology ; Stages 0 , I , II , IIIA , IIIB Clinical diagnosis Major Depressive Disorder ( DSMIVTR ) Hospital Anxiety Depression Scale ( Zigmond Snaith , 1983 ) depression subscale score 11 great Montgomery Asberg Depression Rating Scale ( MADRS ; Montgomery Asberg , 1979 ) score 25 great Screening Baseline visit Use antidepressant previous episode major depression past indication affect patient ’ inclusion study . During current episode major depressive disorder , state Exclusion criterion , failure respond one adequate trial antidepressant exclude patient study since study “ treatmentresistant depression ” . During study , patient may use antidepressant . Presence another current clinically significant Axis I disorder like bipolar disorder , schizophrenia , panic disorder Current ( past 6 month ) comorbid active substance abuse dependence Failure respond one adequate trial antidepressant current episode MDD A reduction MADRS score 20 % great Screening Baseline visit Clinically significant laboratory abnormality judgment Investigator would increase risk adverse effect bupropion Pregnant lactate woman History eat disorder , seizure , head injury , intracranial pathology condition usually contraindication use bupropion XL Previous allergy intolerance bupropion Patients judge significant suicidal risk</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>